<div id="readability-page-1">Cue Biopharma Inc. ( CUE ) shares surged 67.57% overnight to $24.70 on Thursday after the company simultaneously announced a $30 million private investment in public equity financing, an exclusive Phase 2 anti-IgE antibody license and a CEO appointment. <h2>$30 Million Raise Funds Pipeline Expansion</h2> The PIPE, expected to close around May 4, involves pre-funded warrants for up to 2.72 million shares at an effective price of $11. Net proceeds will be used to support the acquisition and development of Ascendant-221, a humanized anti-IgE monoclonal antibody designed to neutralize free IgE and reduce the production of new IgE, targeting major pathways involved in allergic disease. The funds will also be allocated toward general corporate purposes and working capital needs. <h2>Phase 2 Anti-IgE Asset</h2> Separately, CUE licensed Ascendant-221 from the biotechnology company Ascendant Health Sciences for a $15 million upfront fee, plus up to $676.5 million in potential development, regulatory and commercial milestone payments. The company also appointed Shao-Lee Lin, M.D., Ph.D., as CEO, succeeding interim chief Lucinda Warren. Lin previously founded biotechnology company ACELYRIN and took it public within three years at a valuation exceeding $2 billion, while contributing to approved medicines including TEPEZZA, SKYRIZI and RINVOQ. <h2>Trading Metrics, Technical Analysis</h2> Cue Biopharma ( CUE ) has a market capitalization of $47.98 million, with a 52-week high of $15.43 and a 52-week low of $0.17. The small-cap stock has declined 34.92% over the past 12 months. Cue Biopharma ( CUE ) is trading at about 95.48% of its 52-week range, indicating it remains closer to the upper end. Price Action: CUE closed the regular session up 13.38% at $14.74, according to Benzinga Pro. Benzinga's Edge Stock Rankings indicate that CUE is experiencing long-term consolidation along with medium and short-term upward movement. &lt;figure class=&#34;wp-block-image aligncenter size-full is-resized&#34;&gt;<img width="431" height="269" src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/01010431/image-1-1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/01010431/image-1-1.png"/>&lt;/figure&gt; Photo courtesy: Shutterstock Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Read Also: Beyond Meat Stock Is Trending Overnight: Here's What You Should Know </div>

Cue Biopharma Inc. (CUE) 的股價上漲了 67.57%，達到 24.70 美元，此次上漲是由於公司宣佈了一項 3000 萬美元的私人投資、一項二期抗 IgE 抗體的許可，以及任命 Dr. Shao-Lee Lin 為首席執行官。此次 PIPE 融資將支持 Ascendant-221 的開發，這是一種抗 IgE 單克隆抗體，以及公司的整體運營需求。CUE 的市值為 4798 萬美元，過去一年股價下跌了 34.92%，但目前交易價格接近其 52 周高點

Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

Cue Biopharma 的股票在一夜之間飆升了超過 65%：是什麼原因導致的？